Merck: another priority review granted to Keytruda
(CercleFinance.com) - Merck said that its immunotherapy Keytruda has been granted a priority review status by the US Food and Drug Administration for the treatment of head and neck cancer, which thereby accelerates its regulatory approval.
The FDA has accepted a new supplemental Biologics License Application (sBLA) for the drug for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), the company said in a statement on Monday.
The FDA has set a decision date for 10 June 2019.
Keytruda is already indicated for the treatment of numerous cancers, such as lung cancer and Hodgkin lymphoma.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The FDA has accepted a new supplemental Biologics License Application (sBLA) for the drug for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), the company said in a statement on Monday.
The FDA has set a decision date for 10 June 2019.
Keytruda is already indicated for the treatment of numerous cancers, such as lung cancer and Hodgkin lymphoma.
Copyright (c) 2019 CercleFinance.com. All rights reserved.